Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups
Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (n.c.a) 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide) compared to everolimus from its Phase 3 COMPETE trial in Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Study investigator Jaume Capdevila, MD, PhD, presented the data in an oral presentation at the European Society for Molecular Oncology (ESMO) Congress, held October 17-21, 2025 in Berlin, Germany.
As announced in January and at ENETS in March 2025, the Phase 3 COMPETE trial met its primary endpoint, demonstrating a statistically significant improvement in mPFS (p
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Published 3 weeks ago
Oct 18, 2025 at 9:15 AM
Positive
Auto